Improvement of vascular dysfunction and blood lipids of insulin-resistant rats by a marine oil-based phytosterol compound

Lipids
J C RussellP J Dolphin

Abstract

The syndrome that is characterized by obesity, insulin resistance, and hyperlipidemia is increasingly prevalent in all prosperous societies. It is now recognized as a major contributor to cardiovascular disease. Vascular dysfunction in the form of hypercontractility and impaired nitric oxide-mediated relaxation is a significant component of cardiovascular disease, predisposing to ischemic events. The JCR:LA-cp strain of rats exhibits all major aspects of the obesity/insulin resistance syndrome, including vascular dysfunction and ischemic lesions of the heart. Dietary lipid intake may have a marked effect on plasma lipid levels and, potentially, on vascular disease. We have investigated the effects of a novel preparation, ONC101 (a phytosterol esterified with fish oil), on plasma lipids and vascular function in the insulin-resistant JCR:LA-cp rat. Treatment of obese male rats with ONC101 from 8 to 12 wk of age resulted in no change in plasma lipid concentrations at 0.5 g/kg body weight. At the higher dose of 2.6 g/kg, plasma TG fell 50% (1.26 vs. 2.59 mmol/L, P < 0.002) and cholesterol esters were significantly reduced (1.34 vs. 1.61 mmol/L, P < 0.002). Food intake and body weights were unaffected by ONC101 treatment. At the low...Continue Reading

References

Dec 1, 1991·Experimental and Molecular Pathology·J C RussellP J Dolphin
Nov 1, 1989·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·J C RussellP J Dolphin
Oct 14, 1988·Biochimica Et Biophysica Acta·P J DolphinJ C Russell
Nov 16, 1995·The New England Journal of Medicine·T A MiettinenE Vartiainen
Apr 11, 1996·The New England Journal of Medicine·J P DesprésP J Lupien
Mar 1, 1997·Canadian Journal of Physiology and Pharmacology·P J JonesC A Vanstone
Apr 4, 1998·The American Journal of Cardiology·S M Grundy
Apr 8, 1998·Circulation·A M Gotto
Jun 6, 1998·Canadian Journal of Physiology and Pharmacology·S F O'BrienJ C Russell
Jul 25, 1998·Atherosclerosis·M RichardsonJ C Russell
Jun 25, 1999·Metabolism: Clinical and Experimental·J C RussellP J Dolphin
Jul 27, 1999·Lipids·A LeafG E Billman
Sep 9, 2000·Arteriosclerosis, Thrombosis, and Vascular Biology·J HultheB Fagerberg

❮ Previous
Next ❯

Citations

Jul 10, 2010·Cardiovascular Drugs and Therapy·Rafael BitzurArdon Rubinstein
Sep 8, 2009·The Journal of Nutritional Biochemistry·Michelle A Micallef, Manohar L Garg
Oct 14, 2004·The Journal of Allergy and Clinical Immunology·Jennifer K PeatStephen R Leeder
Oct 24, 2006·The Journal of Nutrition·Heather E RasmussenTimothy P Carr

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.